Bengaluru, Karnataka, India, July 2025 — Jubilant Biosys Limited has announced the appointment of Venugopala Reddy Pagadala as Vice President & Chief Financial Officer – CRDMO. In this pivotal role, Venugopala will lead the finance function across all business segments and operational sites within the CRDMO division, reinforcing the company’s commitment to financial discipline, strategic alignment, and operational excellence.
Venugopala joins Jubilant Biosys from Dr. Reddy’s Laboratories, where he most recently served as Cluster Finance Head – CTOs (API). At Dr. Reddy’s, he oversaw finance for eight global manufacturing units and played a critical role in co-piloting business efforts that generated over $1 billion in sales. His tenure was marked by a strong focus on cost leadership, financial controls, compliance, and long-term value creation.
Before Dr. Reddy’s, he was associated with Syngene International Limited (Biocon Group) as Head of Business Finance – CRO, where he managed a business portfolio worth over $250 million and drove profitable growth, automation, and strategic financial planning. His expertise in designing customized pricing models and ensuring governance across business units made a lasting impact on the company’s financial performance.
Earlier in his career, Venugopala spent nearly six years at Cipla, where he held diverse leadership roles including Head Finance – API, CGA & US Specialty Business, Finance Controller – FP&A International Business, and Head Finance – Sri Lanka. His contributions ranged from demand planning and business growth initiatives to overseeing financial reporting and statutory compliance across international markets.
Venugopala also brings valuable experience from his time at Nestlé and Bharat Petroleum Corporation Limited, where he led cross-functional financial operations including budgeting, commercial strategy, logistics, taxation, and credit control. Across these roles, he consistently demonstrated an ability to align finance with broader business objectives.
A Chartered Accountant, Company Secretary, and Cost Accountant, Venugopala blends financial expertise with legal and operational insight. His strong academic credentials and multidisciplinary capabilities make him exceptionally equipped to guide Jubilant Biosys’s CRDMO vertical toward sustainable growth.
Jubilant Biosys Limited (JBL), a subsidiary of Jubilant Pharmova, is a leading integrated CRDMO (Contract Research, Development & Manufacturing Organization) that provides end-to-end solutions in drug discovery and development. With capabilities spanning structural biology, computational chemistry, medicinal and synthetic chemistry, ADME-PK, in-vitro and in-vivo biology, process R&D, and IND-enabling GLP toxicology, Jubilant serves a global clientele across the pharmaceutical, biotech, agrochemical, and specialty chemical sectors.
JBL’s offerings support the full drug discovery cycle—from target identification and lead optimization to preclinical candidates—across therapeutic areas such as oncology, metabolic disorders, CNS, pain, and inflammation. The company operates through state-of-the-art research centers and GMP-compliant manufacturing sites in India.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
